29
July 2025
Alphamab Oncology Announces Anti-HER2 Biparatopic ADC JSKN003 Obtained Orphan Drug Designation from the U.S. FDA for the Treatment of GC/GEJ
The designation of JSKN003 will be beneficial to obtain relevant policy supports for subsequent research and development, registration, and commercialization in the U.S.
